Xu Zhu

Gunagratinib, a highly selective irreversible FGFR inhibitor, in patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring FGFR pathway alterations: A phase IIa dose-expansion study.

Xiao‐Yu Yin, Wei Li, Yufeng Cheng, 2023, Journal of Clinical Oncology.